Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand Is Supporting Development Across The Chronic Plaque Psoriasis Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Chronic Plaque Psoriasis Market?

The chronic plaque psoriasis market has experienced strong expansion in recent years. It is forecast to grow from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The historical increase in this market can be attributed to an improved diagnosis of autoimmune skin disorders, the wider availability of topical therapies, a heightened awareness of psoriasis management, the expansion of dermatology clinics, and enhanced access to specialty drugs.

The chronic plaque psoriasis market is expected to witness significant expansion in the upcoming years. It is projected to achieve a size of $30.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. The projected increase in this period stems from the accelerated development of next-generation biologics, the increasing use of oral immunomodulators, the expansion of precision dermatology techniques, a heightened focus on patient-centric treatment approaches, and increased funding in autoimmune disease research. Notable trends for the forecast period include the growing acceptance of biologic therapies, a rise in the application of targeted small molecule drugs, an increasing emphasis on individualized dermatology care, the broadening availability of oral treatment choices, and a stronger focus on sustained disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

Which Growth Drivers Are Expected To Support The Chronic Plaque Psoriasis Market Forward?

The future expansion of the chronic plaque psoriasis market is anticipated to be driven by the rising occurrence of immune system dysfunction. Immune system dysfunction refers to a state where the immune system fails to operate effectively, leading to increased susceptibility to infections, autoimmune diseases, and cancer. This growth in immune system dysfunction cases is attributed to factors such as genetic predispositions, environmental triggers, malnutrition, chronic stress, and the escalating prevalence of autoimmune diseases and infections like HIV. Chronic plaque psoriasis treatment is essential for regulating immune system dysfunction, as the immune system mistakenly triggers an overproduction of skin cells, resulting in inflammation and the formation of plaques. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these numbers expected to increase by 2040 to approximately 280,040 males and 479,828 females. Consequently, the increasing cases of immune system dysfunction are fueling the growth of the chronic plaque psoriasis market.

How Is The Chronic Plaque Psoriasis Market Structured Across Different Market Segments?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

Which Trends Are Guiding The Development Of The Chronic Plaque Psoriasis Market?

Leading companies within the chronic plaque psoriasis market are concentrating on creating advanced therapies, including IL-17A and IL-17F inhibitors, aiming to improve treatment options for the condition. These inhibitors are specific biologic drugs designed to obstruct interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines contributing to the immune response, thereby lessening inflammation in autoimmune conditions such as chronic plaque psoriasis. As an illustration, in October 2023, UCB S.A., a biopharmaceutical firm from Belgium, disclosed that BIMZELX (bimekizumab-bkzx) received approval from the U.S. Food and Drug Administration (FDA) for treating adults with moderate to severe plaque psoriasis who qualify for systemic or phototherapy treatments. Bimekizumab stands as the inaugural approved medication for psoriasis uniquely formulated to specifically target and suppress interleukin 17A (IL-17A) and interleukin 17F (IL-17F), critical cytokines central to inflammatory pathways. The approval of this drug stemmed from data collected across three Phase 3 multicenter trials, namely BE READY, BE VIVID, and BE SURE, which collectively evaluated its safety and effectiveness in 1,480 individuals suffering from moderate to severe plaque psoriasis.

Which Organizations Are Involved In The Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

Access The Complete Chronic Plaque Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Region Holds The Largest Share In The Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Chronic Plaque Psoriasis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

Pancreatic Cancer Diagnostic Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Invasive Ductal Carcinoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795